1400876-94-9

Upstream product

• 1400877-76-0 4-(ethylthio)-6-phenylpyrrolo[1,2-b]pyridazine-3-carboxamide 
• 3228-51-1 L-threoninol 
• 1400690-23-4 6-bromo-4-(ethylthio)pyrrolo[1,2-b]pyridazine-3-carboxamide 
• 1400580-14-4 6-bromo-4-chloropyrrolo[1,2-b]pyridazine-3-carbonitrile 
• 1400580-13-3 6-bromo-4-hydroxypyrrolo[1,2-b]pyridazine-3-carbonitrile 
• 1400580-12-2 methyl 1-amino-4-bromo-1H-pyrrole-2-carboxylate methanesulfonic acid salt 
• 1400580-11-1 6-bromo-4-chloropyrrolo[1,2-b]pyridazine-3-carboxamide 
• 1400877-77-1 4-(ethylsulfinyl)-6-phenylpyrrolo[1,2-b]pyridazine-3-carboxamide 
• 35302-72-8 pyrrol-2-yl trichloromethyl ketone 
• 934-05-4 methyl 4-bromo-1H-pyrrole-2-carboxylate 
• 72652-32-5 1-(4-bromo-1H-pyrrol-2-yl)-2,2,2-trichloroethanone 

Relevant academic research and scientific papers

Discovery of a JAK1/3 Inhibitor and Use of a Prodrug to Demonstrate Efficacy in a Model of Rheumatoid Arthritis

The four members of the Janus family of nonreceptor tyrosine kinases play a significant role in immune function. The JAK family kinase inhibitor, tofacitinib 1, has been approved in the United States for use in rheumatoid arthritis (RA) patients. A number

PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES

Disclosed are compounds of formula (I) and pharmaceutically acceptable salts thereof. The compounds of formula (I) inhibit tyrosine kinase activity of JAK3, thereby making them useful for the treatment of inflammatory and autoimmune diseases.